blonanserin / Generic mfg. - LARVOL DELTA

A Case of Meige Syndrome in a Pediatric Patient With Schizophrenia. (PubMed, Clin Case Rep) - "We stopped giving him the same medications that had been used during his previous hospitalizations (risperidone, olanzapine, aripiprazole, lurasidone, and paliperidone, paliperidone palmitate (a long-acting injectable), asenapine, and blonanserin). We then started giving him clozapine, gradually increasing the dose to 125 mg. Following this treatment intervention, the dystonic symptoms resolved completely, and the psychiatric symptoms stabilized."

Journal • CNS Disorders • Dystonia • Movement Disorders • Pediatrics • Psychiatry • Schizophrenia

Pharmacological treatment of schizophrenia: Japanese Expert Consensus 2025. (PubMed, Schizophrenia (Heidelb)) - "First-line antipsychotics varied by predominant symptoms: risperidone, brexpiprazole, olanzapine, paliperidone, and blonanserin for positive symptoms; aripiprazole and brexpiprazole for negative symptoms and cognitive impairment; aripiprazole, brexpiprazole, lurasidone, olanzapine, and quetiapine for depression and anxiety; brexpiprazole, aripiprazole, and olanzapine for disorganized thinking; olanzapine and risperidone for excitement and aggression; and aripiprazole, brexpiprazole, and lurasidone for social integration...Switching to clozapine was the treatment of choice for treatment-resistant schizophrenia...Second-generation antipsychotics were rated as first- or second-line options in most situations, whereas first-generation antipsychotics were generally rated as third-line. These recommendations provide practical guidance for treatment selection and shared decision-making in clinically challenging situations not adequately addressed by existing evidence alone."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Diabetes • Metabolic Disorders • Mood Disorders • Movement Disorders • Psychiatry • Schizophrenia

Comparison of Neurocognitive Effects of Blonanserin, Olanzapine, Aripiprazole, and Risperidone in Drug-Naïve First-Episode Schizophrenia. (PubMed, Neuropsychiatr Dis Treat) - "Initial antipsychotic treatment in drug-naïve FES patients is associated with neurocognitive benefits, particularly in processing speed and working memory. Furthermore, blonanserin may offer advantages in ameliorating learning and memory deficits compared to risperidone."

Journal • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Antipsychotic dose and efficacy for acute schizophrenia spectrum disorders: an updated systematic review and dose-response meta-analysis. (PubMed, EClinicalMedicine) - "Dose-response curves of most antipsychotics on overall symptoms in people with acute exacerbations of schizophrenia were hyperbolic, reaching plateau within the lower-to-medium approved dose ranges, around 3-5 mg risperidone dose equivalents. There was low to very low certainty of evidence regarding the dose-response relationships of amisulpride, blonanserin, cariprazine, clozapine, haloperidol, lumateperone and ziprasidone. We did not find enough studies to conduct dose-response meta-analysis for olanzapine/samidorphan, xanomeline/trospium, and zotepine...This meta-analysis was conducted within the framework of a larger project funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; grant #468853597) and within activities of the German Center for Mental Health (Deutsches Zentrum für Psychische Gesundheit, DZPG), Munich-Augsburg partner site, funded by the Federal Ministry of Research, Technology and Space (BMFTR, grant #01EE2303B). This..."

Journal • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Bilateral hand-restricted drug eruption induced by blonanserin: a case report. (PubMed, Front Psychiatry) - "The patient's psychiatric symptoms remained stable on quetiapine monotherapy. This is the first report of a bilateral hand-limited drug eruption due to blonanserin and underscores that prompt withdrawal upon rash appearance is important for patient comfort and aligns with good clinical practice."

Journal • Atopic Dermatitis • CNS Disorders • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Psychiatry

Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders: A Systematic Review, Meta-Analysis, and Long-Term Prospective Evidence. (PubMed, J Child Adolesc Psychopharmacol) - "Several SGAs produce short-term symptom reductions versus placebo in children and adolescents with schizophrenia-spectrum disorders, with heterogeneity in TEAE risk across agents. Evidence for long-term maintenance and continuation remains limited, underscoring the need for adequately powered randomized continuation trials to guide sustained treatment in this population."

Journal • Retrospective data • Review • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

A rare case of isovaleric acidemia and schizophrenia: a case report. (PubMed, BMC Psychiatry) - "In this case description, the authors describe a rare clinical case in which the patient presents with IVA and schizophrenia. This case discusses the potential pathways through which IVA may precipitate the onset of schizophrenia."

Journal • CNS Disorders • Mental Retardation • Metabolic Disorders • Psychiatry • Rare Diseases • Schizophrenia

Severity and influencing factors of hyperprolactinemia in hospitalized schizophrenia patients: a cross-sectional study. (PubMed, Front Psychiatry) - "The ordered multivariate logistic regression model showed that HPRL severity was negatively correlated with aripiprazole use, male sex, fasting glucose, aspartate aminotransferase (AST), and follicle-stimulating hormone (FSH), but positively correlated with the use of sulpiride, paliperidone, amisulpride, risperidone, blonanserin, trihexyphenidyl, and anxiolytics. HPRL is highly prevalent in schizophrenia patients, with distinct clinical profiles across severity levels. HPRL severity is associated with specific antipsychotics, anxiolytics, trihexyphenidyl, and metabolic indicators, underscoring the need for risk stratification and individualized management."

Journal • Observational data • CNS Disorders • Psychiatry • Schizophrenia • PRL

High-Fat Meal Increase Blonanserin Bioavailability 5-Fold in Chinese Healthy Subjects. (PubMed, Drug Des Devel Ther) - "Blonanserin was well tolerated in most subjects under both fasting and fed conditions, and food intake did not significantly alter its safety profile. These findings highlight the need to consider food effects when determining clinical dosing regimens."

Clinical • Journal

Post-marketing safety analysis of blonanserin: a retrospective pharmacovigilance study using the Japanese Adverse Drug Event Report database (2008-2024). (PubMed, Eur J Pharmacol) - "This large-scale real-world pharmacovigilance analysis delineates the ADE profile of blonanserin, highlighting the predominance of early-onset adverse events and uncovering new potential risks. These results contribute valuable safety information to clinical practice and underscore the need for further prospective studies to validate and expand upon these observations."

Adverse events • Journal • P4 data • Retrospective data • Cardiovascular • CNS Disorders • Dyslipidemia • Dystonia • Hypertriglyceridemia • Movement Disorders • Psychiatry • Pulmonary Embolism • Respiratory Diseases • Schizophrenia

Steroid-responsive autoimmune psychosis with cerebrospinal fluid-restricted oligoclonal bands and positive tissue-based assay findings: a case series of three patients. (PubMed, BMC Psychiatry) - "Cerebrospinal fluid-restricted oligoclonal bands and tissue-based assay in cerebrospinal fluid could both provide sufficient evidence for autoimmune psychosis in the absence of clear neurological symptoms. For patients with mild psychiatric symptoms, low-dose of steroids may also be a treatment option. Autoimmune psychosis should be considered when antipsychotic drugs or modified electroconvulsive therapy are not effective in patients with psychotic disorders."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Immunology • Psychiatry • Schizophrenia

Meta-Analysis of the Effect of Blonanserin in Treating Patients with Schizophrenia. (PubMed, Noro Psikiyatr Ars) - "We selected five commonly used antipsychotic drugs, namely haloperidol, risperidone, olanzapine, paliperidone and aripiprazole. Blonanserin is effective and safe in the treatment of schizophrenia, which is beneficial for guiding the clinical practice of schizophrenia treatment. However, more high-quality studies are needed in the future to validate its effect."

Journal • Retrospective data • Review • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Insomnia • Pain • Psychiatry • Schizophrenia • Sleep Disorder

Effectiveness and safety of blonanserin monotherapy for first-episode schizophrenia with and without prominent negative symptoms: A prospective study. (PubMed, World J Psychiatry) - "Blonanserin effectively alleviated the clinical symptoms of first-episode schizophrenia with an acceptable safety profile. High-dose blonanserin is particularly beneficial for patients with PNS in the acute phase of first-episode schizophrenia. However, due to the limitation of ADR reporting the real world, the ADR incidence observed in this study may be underestimated."

Journal • Monotherapy • CNS Disorders • Psychiatry • Schizophrenia

Impact of antipsychotics on prolactin levels in youth with psychiatric disorders: A cross-sectional study. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry) - "Approximately 40 % of pediatric patients treated with antipsychotics exhibited abnormal prolactin levels. Clinicians should routinely monitor prolactin levels and consider prolactin-related side effects when prescribing antipsychotics to children and adolescents. These findings emphasize the importance of tailored antipsychotic therapy to minimize the adverse effects in this vulnerable population."

Journal • Observational data • CNS Disorders • Mental Retardation • Pediatrics • Psychiatry • PRL

Evaluating the pharmacokinetics and safety of blonanserin tablets and Lonasen®: a randomized, open-label, two-period, two-sequence, self-crossover phase I clinical trial. (PubMed, Front Pharmacol) - "Both formulations were found to be safe and well tolerated. http://www.chinadrugtrials.org.cn/index.html, identifier CTR20230703."

Journal • P1 data • PK/PD data • CNS Disorders • Psychiatry • Schizophrenia

A clinical observation of the efficacy and safety of blonanserin in treatment-resistant schizophrenia (ChiCTR) - P=N/A | N=60 | Recruiting | Sponsor: Taiyuan Psychiatric Hospital; Taiyuan Psychiatric Hospital

New trial • CNS Disorders • Psychiatry • Schizophrenia

Population pharmacokinetics of blonanserin in Japanese adolescent and adult patients with schizophrenia. (PubMed, Drug Metab Pharmacokinet) - "Bayesian estimates of apparent clearance suggested no effects of age in adolescents between 12 and 18 years old. Together, these results reveal the pharmacokinetic characteristics of blonanserin over a wide age range and support the appropriateness of the approved dosing regimen for adolescent patients with schizophrenia in Japan."

Journal • PK/PD data • CNS Disorders • Psychiatry • Schizophrenia • CYP3A4

Assessment of factors associated with antipsychotic-induced weight gain: A nationwide cohort study. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry) - "The findings of this study suggest that the risk of AIWG incidence may be estimated by assessing the type of concomitant medication and its duration of use, type of newly initiated antipsychotic, and background factors prior to initiation of antipsychotic treatment."

Journal • CNS Disorders

Blonanserin-Associated Leukopenia: Two Case Reports. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal • Hematological Disorders • Leukopenia

Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophrenia. (PubMed, World J Psychiatry) - "Patients in the acute phase with more severe symptoms, shorter current episode duration, fewer previous episodes, and a lower psychotropic drug load derived the greatest benefit from treatment with BNS."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials. (PubMed, Schizophr Res) - "Our study suggests that differences in efficacy between blonanserin and other antipsychotics are small and that blonanserin has a different tolerability profile than haloperidol and risperidone."

Journal • Retrospective data • Review • CNS Disorders • Movement Disorders • Psychiatry • Schizophrenia

A case report of adolescent lactation due to the drug blonanserin. (PubMed, BMC Psychiatry) - "Although Blonanserin's clinical trials have reported rare adverse reactions like elevated prolactin levels and even lactation, caution is still needed in clinical application of the drug. This case is expected to improve psychiatrists' choice of antidepressant therapy in combination with antipsychotic drugs."

Journal • CNS Disorders • Depression • Psychiatry

Preparation and release pattern study of long-term controlled release Blonanserin microspheres. (PubMed, Int J Pharm) - "When the ratio of 15 kDa and 75 kDa was 1:9 (F3), the Bn-MS had a low burst release rate, moderate release rate, no release hysteresis period, a long release period of up to 35 days, and a stable release pattern close to the zero level. The results of the release mechanism study indicated that the hybrid PLGA improved the release behavior of the microspheres by adjusting the dissolution degradation rate of Bn-MS, which in turn affected the release mechanism of the microspheres."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning. (PubMed, BMC Psychiatry) - "The 104-week treatment outcomes were comparable between groups; the overall trend of improvement in remission rate, safety, and QOL suggests the importance of continued treatment."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Cytochrome P450 in a bottle (ACS-Fall 2024) - "The expansion of scope was guided and quantitatively evaluated by a chemoinformatics analysis. MnCF3PDP is demonstrated to oxidize drugs and drug-like molecules (for example antipsychotic blonanserin, COX-2 inhibitors, fungicide penconazole) with the same site-selectivities as promiscuous liver CYPs to furnish metabolites on large scale (gram-scales) in 1-2 steps from the drug or drug precursor."

CNS Disorders